Breckenridge Pharmaceutical Inc, Teva, Natco cancer news

Teva’s Cephalon Inc. subsidiary filed suit against Breckenridge and partner Natco in the U.S. District Court for the District of Delaware alleging Breckenridge’s ANDA for a generic version of Cephalon’s Treanda bendamustine infringes U.S. Patent Nos. 8,445,524; 8,436,190; and 8,609,863. The ANDA contained a Paragraph IV certification saying that the patents are invalid, unenforceable and/or would not be infringed by Breckenridge’s product. The ‘524 patent expires in March 2029, the ‘190 patent expires in October 2030 and the ‘863 patent expires in January 2026. In its response, Breckenridge said it lacked “sufficient knowledge or information to admit or deny” the infringement allegations and therefore denies them. ...